Pharmacokinetics of moxifloxacin in an infant with Mycoplasma hominis meningitis.
Treatment of Mycoplasma hominis meningitis in infants is limited by a lack of consensus regarding therapy and limited pharmacokinetic data for agents to which M. hominis is susceptible. We report the successful treatment of a premature infant suffering from M. hominis meningitis with doxycycline and moxifloxacin and provide a pharmacokinetic profile of moxifloxacin.
Department of Pediatrics, Duke University Medical Center, Durham, NC 27599, USA.
Kevin M
KM
Watt
Matthew M
MM
Massaro
Brian
B
Smith
Michael
M
Cohen-Wolkowiez
Daniel K
DK
Benjamin
Matthew M
MM
Laughon
D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D001372:Aza Compounds / Q000008:administration & dosage / Q000493:pharmacokinetics*; D002648:Child; D002675:Child, Preschool; D004318:Doxycycline / Q000008:administration & dosage; D005260:Female; D024841:Fluoroquinolones; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D016920:Meningitis, Bacterial / Q000188:drug therapy* / Q000382:microbiology; D000077266:Moxifloxacin; D009175:Mycoplasma Infections / Q000188:drug therapy* / Q000382:microbiology; D019535:Mycoplasma hominis / Q000302:isolation & purification*; D011247:Pregnancy; D011804:Quinolines / Q000008:administration & dosage / Q000493:pharmacokinetics*; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D004318:Doxycycline; D000077266:Moxifloxacin